Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

  • There is currently no data for HEIQ

Trading Update

26 Jan 2021 07:00

RNS Number : 8338M
HeiQ PLC
26 January 2021
 

This article is not intended to be distributed in the USA.

 

26 January 2021

 

HeiQ Plc

("HeiQ" or "the Company")

 

Trading Update

 

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to provide a trading update for the financial year ended 31 December 2020 ("FY 2020" or "the Period").

 

The Company expects to report that revenue for FY 2020 exceeded market expectations. This was due to a robust performance delivered by HeiQ's core portfolio of products, including a particularly strong sales performance from its antimicrobial technology, HeiQ Viroblock, which was launched during the Period. Since then, it has been applied to over 1 billion facemasks and won the Swiss Technology Award in Q4 2020.

 

Operating profit for FY 2020 is anticipated to be in line with market expectations, even after the record levels of investment made by the Company in H2 2020 which will provide a strong platform from which it can achieve its long-term goals.

 

HeiQ's trading for the full year to 31 December 2021 has commenced in line with market expectations and management is confident about the Company's prospects for the year ahead.

 

HeiQ co-founder and CEO Carlo Centonze said:

 

"2020 was a milestone year for HeiQ, characterised by rapid growth and innovation. Not only did we respond quickly to the COVID-19 outbreak by bringing HeiQ Viroblock to market early, we did so while also delivering robust sales growth for many existing products within our 200-strong portfolio of novel textile technologies. These achievements solidified our position as a profitable and fast-growing pioneer in the $24 billion textile chemicals market.

 

"Managing to deliver such a strong performance, whilst also executing on our ambition to list in London through an oversubscribed £60 million fundraise, is testament to the hard work and dedication of our global team. Liquidity in the group remains strong and I am confident that continuing investments will allow us to continue to bring new technologies to market at high pace, whilst also building on the strong sales momentum delivered last year. We will monitor the global markets which continue to be affected by the pandemic but are pleased to have started trading in line with market expectations for the current financial year."

 

This announcement contains inside information.

 

 

For further information, please contact:

 

HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Arlington Group Asset Management Limited (Financial Advisor and Joint Broker)

Charles Cannon Brookes

+44 (0) 207 389 5017

Cenkos Securities plc (Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Robin Tozer / Megan Kovach

+44 (0) 20 3757 6882

HeiQ@secnewgate.co.uk

 

 

About HeiQ

HeiQ is a pioneer and at the forefront of global technology in the $10 billion antimicrobial fabrics and $24 billion textile chemicals market. With the focus on materials and textile innovation, HeiQ has created some of the most effective, durable and high-performance technologies and textile effects in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands.

 

HeiQ is a high intellectual capital company which has successfully built up a reputation in textile technologies, having won multiple awards and innovating with leading eco-conscious brands such as Patagonia.

 

Led by an experienced management team, HeiQ rapidly researches new solutions for partners, quickly delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

 

HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKPBQCBKDPDB
Date   Source Headline
18th Nov 20247:00 amRNSDirector/PDMR Shareholding
14th Nov 20247:00 amRNSUpdate on Delisting and Potential Capital Raise
31st Oct 20247:01 amRNSNotice of AGM
31st Oct 20247:00 amRNSResults for 18-month period ended 30 June 2024
24th Oct 202411:26 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSRestructuring and Delisting
18th Sep 202411:45 amRNSHolding(s) in Company
16th Sep 20249:03 amRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSTrading Update
16th Jul 20247:00 amRNSHeiq AeoniQ Capital Raising
30th May 20247:00 amRNSChange of Auditor
22nd Apr 20247:00 amRNSHeiQ Synbio Secures Ecolab Contract Win
16th Apr 20242:17 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSUnaudited Interim Results
18th Mar 202412:41 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSHolding(s) in Company
14th Mar 20241:23 pmRNSCompletion of Fundraising, PDMR & Audit Update
13th Mar 20242:26 pmRNSResult of General Meeting
12th Mar 20247:00 amRNSBoard Changes
23rd Feb 20247:00 amRNSResult of Retail Offer
16th Feb 20247:00 amRNSResult of Placing
15th Feb 20245:49 pmRNSRetail Offer
15th Feb 20245:46 pmRNSAcquisition, Fundraising, Trading Update & GM
6th Dec 20232:46 pmRNSAgreed Changes to Concert Party
4th Dec 20237:00 amRNSDirector/PDMR Dealing
1st Dec 20233:04 pmRNSResult of General Meeting
30th Nov 20237:06 amRNSStatement Confirming Settlement
27th Nov 20237:00 amRNSBoard Appointment
8th Nov 20237:00 amRNSNotice of General Meeting
3rd Nov 20239:14 amRNSHolding(s) in Company
3rd Nov 20237:05 amRNSHolding(s) in Company
31st Oct 20237:43 amRNSFiling of Annual Report & Restoration of Trading
31st Oct 20237:30 amRNSRestoration - HEIQ PLC
30th Oct 20237:01 amRNSInterim Results
30th Oct 20237:00 amRNSResults for year ended 31 December 2022
23rd Oct 20237:00 amRNSNotice of Results and Audit Update
29th Sep 20237:00 amRNSAccounts Update
6th Jul 20237:00 amRNSMAS Holdings invests in HeiQ AeoniQ
29th Jun 20232:16 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
6th Jun 20237:00 amRNSNotice of AGM
2nd May 20237:44 amRNSTemporary Suspension of Trading in Ordinary Shares
27th Apr 20233:55 pmRNSTemporary Suspension
13th Jan 20232:09 pmRNSUpdate re. admission of Consideration Shares
12th Jan 20237:00 amRNSCompletion of Acquisition
10th Jan 20237:00 amRNSDirector / PDMR Dealing
6th Jan 20237:00 amRNSDirector / PDMR Dealing
5th Jan 20237:03 amRNSDirector/PDMR Shareholding
4th Jan 20237:00 amRNSTrading Update and Acquisition
14th Dec 20227:00 amRNSIncreased interest in HeiQ Chrisal to 71%

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.